SL Science Holding Limited (SLBT), a biomedical company, on Thursday announced filing a new Master Drug File (MDF) with the U.S. Food and Drug Administration (FDA) to cover exosomes derived from Gamma Delta T (GDT) cells.
A DMF streamlines future regulatory processes by providing the FDA with confidential chemistry, manufacturing, and controls (CMC) data that can be referenced in subsequent applications. The DMF number 044612 for the exosomes was filed by JY BioMed Co Ltd, an investor of the company and the holder of intellectual property (IP) rights for GDT.
GDT technology is being developed for the treatment of solid tumors, such as pancreatic and brain cancers.
Extracellular vesicles like exosomes hold potential for passing through the blood-brain-barrier, thus treating malignancies like glioblastomas. Peer-reviewed research has established that exosomes can cross an intact blood-brain-barrier and reach the central nervous system via a receptor-mediated biological pathway.
Independent studies indicated that exosomes work synergistically with radiotherapy and remains active in immunosuppressive tumor environments. GDT-derived exosomes can also trigger an immune response, directly bringing about tumor cell death.
SLBT closed Thursday at $2.64, up 1.54%. In the afterhours trade, the stock is at $2.58, down 2.27%.
See Also:
News on Adaptin's APTN-101 for glioblastoma; BioArctic and Mesenkia's antibody program targeting glioblastoma; Alpha Tau's radiotherapy for glioblastoma.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.